Our rich pipeline of product candidates demonstrates our leadership in drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record of success. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients.
*Supplemental New Drug Application (sNDA) submitted to FDA in August 2016
**Transition from physical dependence on opioids to VIVITROL®